Seven monoclonal antibodies (MAbs) were produced which recognized equid herpesvirus type 1 (EHV-1). Three MAbs neutralized the subtype 1 virus (strain Army 183) in the presence of complement, but did not neutralize the subtype 2 virus (strain MD). All three MAbs immunoprecipitated an Mr 83K glycoprotein from a detergentsolubilized virion envelope preparation of the subtype 1 virus. The target antigens of the four non-neutralizing MAbs (6Fll, 2A4, 1F10 and 8D9) were identified by immunoblotting against purified EHV-1 virions and had respective apparent Mr values of > 205K, > 205K, 97K and 13K.
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*Titres are expressed as the reciprocal of the highest dilution of ascitic fluid in which the amount of 1251 bound was over twice that bound with MAb 3G9.
l"Titres are expressed as the reciprocal of the highest dilution of ascitic fluid giving 50% plaque reduction in the presence of complement.
:~, Weak fluorescence. §ND, Not determined.
IlThis MAb directed against A/equine/Newmarket/79 (H3N8) influenza virus (Cook et al., 1988) was used as a negative control throughout.
(w/v) linear dextran T 10 (Pharmacia) gradient (60000 g, 1 h, 21 °C). After harvesting, banded material was pelleted (37000 g, 3 h, 4 °C), resuspended, divided into aliquots and stored at -70 °C. Viral stocks were examined by electron microscopy to check the integrity of the envelopes, and purity was assessed by analysis on polyacrylamide gels. Total protein content was assayed using commercially available reagents (Bio-Rad).
MAbs were produced essentially as described by Campbell (1984) . BALB/c mice (10 to 12 weeks old) were immunized with an intraperitoneal injection of 100 pg of purified virus in TE buffer, and after an interval of 6 to 8 weeks the mice were boosted intravenously with 25 gg of virus in phosphate-buffered saline (PBS, pH 7-4). Spleens were removed 3 to 4 days later and fusions performed using the myeloma cell line NSO. Hybridoma culture supernatants were screened by ELISA using purified EHV-1 as antigen. Hybridomas secreting antibodies against EHV-1 were cloned twice by limiting dilution. Ascites fluids were obtained by intraperitoneal injection of 2 x 106 hybridomas into BALB/c mice after priming with 2, 6, 10, 14-tetramethylpentadecane (Sigma). MAbs were partially purified from ascitic fluids by precipitation with 42.5% (w/v) saturated ammonium sulphate and isotyped by ELISA with a panel of rabbit antisera to mouse immunoglobulin subclasses (ICN Pharmaceuticals).
MAbs 8F8, 3D4 and 3E5 were produced from mice immunized with the EHV-1 subtype 1 strain Army 183, whereas MAbs 6Fll, 2A4, 1F10 and 8D9 were produced from mice immunized with the EHV-1 subtype 2 strain MD. These reagents were characterized by radioimmunoassay (RIA), plaque reduction, immunoblotting or immunoprecipitation and an indirect immunofluorescence (IIF) test (Table 1) . For RIA Removawells (Dynatech Laboratories, U.K.) were coated overnight at 4 °C with 100pl of purified EHV-1 subtype 1 and subtype 2 virions (4.8~tg/ml) in coating buffer (0.05 M-NaHCO3/Na2CO3 pH 9.6). Doubling dilutions of ascitic fluids were added to the plate (in triplicate) followed by rabbit anti-mouse immunoglobulins (Dako, Copenhagen, Denmark). Bound antibody was detected by addition of 105 c.p.m, of a25]-labelled Protein A. Five MAbs were found to be subtype cross-reactive, one (8F8) subtype 1-specific and one (1F10) subtype 2-specific (Table 1 ). The reactivities of these MAbs (except 1F 10, which did not react) were confirmed by IIF tests on EHV-1 subtype 1-and subtype 2-infected (0.025 p.f.u./cell) EEL cells grown in eight-well chamber slides (Miles Laboratories) ( Table 1 ). The cells were fixed 24 h post-infection in PBS containing 1.34~ (w/v) formaldehyde (20 min, room temperature) followed by PBS containing 1 ~ (v/v) Nonidet P40 (10 min, room temperature). Fixed, infected monolayers were incubated with 4 ~ (w/v) bovine serum albumin, followed by MAb, rabbit anti-mouse immunoglobulin (Dako) and finally fluorescein isothiocyanate-conjugated goat anti-rabbit immunoglobulin (ICN). No immunofluorescence was detected on mock-infected cell controls.
Complement-dependent and complement-independent neutralization was assayed as follows. Aliquots (0.5ml) of EHV-1 virions containing 500 to 1000 p.f.u, were incubated with equal volumes of heat-inactivated (56 °C, 30 min) ascitic fluids at log10 dilutions ranging from -2 to -6. After 1 h at 37 °C, 200 Izl aliquots were added to EEL monolayers in 5 cm Petri dishes (three dishes per dilution). Control plaque counts were obtained by incubating EHV-1 virions with an equal volume of SF MEM. The plates were incubated at 37 °C for 45 rain, washed twice with SF MEM and overlaid with maintenance medium containing 1.6~ (w/v) CM-cellulose. After incubation at 37 °C for 48 h, plaques were fixed in methanol and stained with 1 ~o (w/v) methylene blue. Complement-dependent neutralization was assayed by the addition of 80 ~1 of guinea-pig complement for 30 min at 37 °C after incubation of virus with ascitic fluid. MAbs 8F8, 3D4 and 3E5 neutralized the subtype 1 virus (strain Army 183) in the presence of guineapig complement (Table 1 ), but not the subtype 2 virus (strain MD).
The target antigens of the three neutralizing MAbs could not be identified by immunoblotting against denatured EHV-1 polypeptides ( Fig. 1 a and b ). They were, however, immunoprecipitated from a detergent-solubilized [3H]glucosamine-labelled virion envelope preparation. As shown in Fig. 1 (c) , all three MAbs recognized an Mr 83K polypeptide in the subtype 1 strain Army 183. On the basis of its relative migrational position in polyacrylamide gels and the fact that [3H]glucosamine can be incorporated into it, the 83K polypeptide probably corresponds to the envelope glycoprotein designated VP 13 by Turtinen & Allen (1982) . The difference in the estimated Mr to that reported by these authors probably corresponds to differences in electrophoretic conditions.
Comparison of neutralization data with results obtained in the RIA and IIF tests ( Table 1 ), suggests that the epitopes on the Mr 83K polypeptide, defined by the neutralizating MAbs, fall into two distinct categories. The first, recognized by MAb 8F8, is subtype 1-specific, while the second, recognized by MAbs 3D4 and 3E5, is subtype cross-reactive. It is interesting, however, that although 3D4 and 3E5 bind to subtype 2 viruses, this reaction does not result in neutralization of virus infectivity. This suggests the existence of functional and/or conformational differences between the subtype 1 polypeptide and its subtype 2 counterpart. Studies to determine whether 3D4 and 3E5 recognize the same epitope or bind within the same antigenic domain have yet to be conducted.
The target antigens of four non-neutralizing MAbs (6Fll, 2A4, 1F10 and 8D9) were identified by immunoblotting against denatured, electrophoretically separated EHV-1 polypeptides ( Fig. 1 a and b) . The subtype cross-reactive MAbs, 6F11 and 2A4, reacted with different, high Mr (> 205K) polypeptide bands in both subtype 1 and subtype 2 viruses. With each subtype, the polypeptide band recognized by 2A4 had a slightly greater electrophoretic mobility than that recognized by MAb 6F11. In the subtype 2 virus the target antigens of 6F11 and 2A4 were of slightly lower apparent Mr than in subtype 1 virus. The Mr values and relative migrational positions indicate that the target antigens of 6F11 and 2A4 correspond to the polypeptides designated VP 1-2 by Turtinen & Allen (1982) . Although these are two of the most abundant envelope-associated polypeptides of EHV-1 (Turtinen & Allen, 1982 ) their functional or immunological significance remains to be determined. Binding of 6F11 and 2A4 did not neutralize virus infectivity; however one previous report suggests some MAbs to VP 2 affect plaque morphology in vitro (Edington et al., 1987) .
Of the remaining MAbs in this report, 1F10 reacted with an Mr 97K polypeptide in the subtype 2 strain MD but did not react with the subtype 1 strain Army 183. This is consistent with the RIA data shown in Table 1 . MAb 8D9 recognized a polypeptide of Mr approx. 13K in both subtype 1 and subtype 2 strains (Fig. 1 a and b) . However, with 8D9, the autoradiographic image of the polypeptide appeared to be weaker in the Army 183 strain than the MD strain, despite the fact that the viral antigens were used at equivalent protein concentrations. This is consistent with the reactivity of 8D9 in IIF tests, and the fourfold higher titre observed in the RIA with MD antigen (Table 1 ). Therefore, it is possible either that there are slight conformational differences between the Army 183 and MD strains in the epitope recognized by 8D9, or that the polypeptide is present in a lower relative abundance in the Army 183 strain. 205' 116-97-66-45" 29- Fig. 1. (a,b) . Immunoblots of MAbs and polyclonal antibodies against EHV-1 subtype 1 (a) (strain Army 183) and subtype 2 (b) (strain MD) virions respectively. Gradient-purified EHV-1 virions were electrophoretically separated in 10 to 30~ (w/v) linear gradient SDS-polyacrylamide gels (Cook et al., 1979) using the discontinuous buffer system of Laemmli (1970) . Mr markers (MW-SDS-200 kit; Sigma) were run in parallel. The virion polypeptides were then transferred electrophoreticaUy to nitrocellulose (Hybond-C; Amersham) and reacted with MAb, rabbit antiserum to mouse immunoglobulins (Dako) and finally ~25I-labelled Protein A. Bound antibodies were visualized by autoradiography (Agfa Gevaert Curix RP 1 X-ray film) and Mr markers were visualized by staining with 0.1 ~ (w/v) Amido black. Lanes 1, polyclonal rabbit antiserum to homologous subtypes (the subtype 2 antiserum recognized a polypeptide of lower electrophoretic mobility than those recognized by either MAb 6F 11 and 2A4, the origin of which has still to be determined); lanes 2, MAb 6F 11 ; lanes 3, MAb 2A4; lanes 4, MAb 1F 10; lanes 5, MAb 8D9; lanes 6, MAb 3E5; lanes 7, MAb 3D4; lanes 8, MAb 8F8; lanes 9, MAb 3G9 (negative control). (c) Electrophoretically separated [3H]glucosaminelabelled EHV-I subtype 1 (strain Army 183) virion polypeptides immunoprecipitated with neutralizing MAbs according to the method described by Allen & Yeargan (1987 This report demonstrates the value of MAbs in dissecting the complex antigenic relationships between subtype 1 and subtype 2 viruses and in identifying strain variation. It also highlights the importance of MAbs in determining neutralizing epitopes, and results presented here suggest that the Mr 83K glycoprotein of EHV-1 subtype 1 may have an important role in the generation of neutralization responses in FiFo. The significance of these neutralizing responses in protection remains to be determined, although it might be predicted, by analogy with herpes simplex virus, that protection would be mediated not only by neutralization with antibody but also by cellular immune responses stimulated by one or more viral glycoproteins (Hall & Katrak, 1986) . Therefore, additional studies are required before the full complement of viral antigens involved in protection can be assessed.
